v3.26.3
Schedule of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Research and development expenses $ 1,792,524 $ 1,899,251 $ 5,594,487 $ 5,291,297
General and administrative expenses 1,655,177 1,576,577 4,951,312 5,097,694
Total operating expenses 3,447,701 3,475,828 10,545,799 10,388,991
Loss from operations $ 3,447,701 $ 3,475,828 10,545,799 10,388,991
Operating Segments [Member]        
Segment Reporting [Line Items]        
Research and development expenses     5,594,000 5,290,000
Change Increase (Decrease), Research and development expenses     $ 304,000  
Change Increase (Decrease), Research and development expenses, percentage     6.00%  
General and administrative expenses     $ 4,951,000 5,098,000
Change Increase (Decrease), General and administrative expenses     $ (147,000)  
Change Increase (Decrease), General and administrative expenses, percentage     (3.00%)  
Total operating expenses     $ 10,545,000 10,388,000
Change Increase (Decrease), Operating expenses     $ 157,000  
Change Increase (Decrease), Operating expenses, percentage     2.00%  
Loss from operations     $ 10,545,000 10,388,000
Change Increase (Decrease), Loss from operations     $ 157,000  
Change Increase (Decrease), Loss from operations, percentage     2.00%  
Operating Segments [Member] | Clinical Research [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 2,322,000 2,335,000
Change Increase (Decrease), Subtotal     $ (13,000)  
Change Increase (Decrease), Subtotal, percentage     (1.00%)  
Operating Segments [Member] | Clinical Research [Member] | OVATION Trials [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 774,000 800,000
Change Increase (Decrease), Subtotal     $ (26,000)  
Change Increase (Decrease), Subtotal, percentage     (3.00%)  
Operating Segments [Member] | Clinical Research [Member] | MRD Study [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 169,000 106,000
Change Increase (Decrease), Subtotal     $ 63,000  
Change Increase (Decrease), Subtotal, percentage     59.00%  
Operating Segments [Member] | Clinical Research [Member] | Placcine Vaccine [Member]        
Segment Reporting [Line Items]        
Subtotal     42,000
Change Increase (Decrease), Subtotal     $ (42,000)  
Change Increase (Decrease), Subtotal, percentage     (100.00%)  
Operating Segments [Member] | Clinical Research [Member] | Other Clinical and Regulatory [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 1,379,000 1,387,000
Change Increase (Decrease), Subtotal     $ (8,000)  
Change Increase (Decrease), Subtotal, percentage     (1.00%)  
Operating Segments [Member] | Non-Clinical R&D and CMC [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 3,272,000 2,955,000
Change Increase (Decrease), Subtotal     $ 317,000  
Change Increase (Decrease), Subtotal, percentage     11.00%  
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Manufacturing & Clinical Supply [Member]        
Segment Reporting [Line Items]        
Subtotal     $ 3,272,000 $ 2,955,000
Change Increase (Decrease), Subtotal     $ 317,000  
Change Increase (Decrease), Subtotal, percentage     11.00%